Commenting on a study into immunotherapy and pancreatic cancer by researchers at St George’s, University of London, published in the British Journal of Cancer, Leanne Reynolds, Head of Research at Pancreatic Cancer UK, said:
"We're excited to hear that this study found the immunotherapy treatment allowed some patients with advanced pancreatic cancer to live significantly longer. On average, someone with advanced disease will live for just two to six months, so a new treatment which could allow them to spend longer with their loved ones could make an enormous difference.
“However, this was a small study which primarily looked at the drug’s safety. We would need to look specifically at its impact on the survival of a larger group of patients with advanced disease to fully understand how promising it is. There are very few treatments for pancreatic cancer and immunotherapy is a very exciting research area for the disease, which is why we are funding a study at Barts Cancer Institute in this area.”